Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Chinês |
| Pubblicazione: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2014-12-01
|
| Serie: | Chinese Journal of Lung Cancer |
| Soggetti: | |
| Accesso online: | http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.05 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|